Model Medicines Secures First US Patent for AI-Discovered Broad-Spectrum Antiviral MDL-001
核心洞察
Model Medicines (搜索) received its first US patent for MDL-001, a broad-spectrum antiviral discovered through AI that targets a conserved viral replication mechanism across multiple virus families.
The company's intellectual property portfolio encompasses 15 patent families providing protection through 2046 for compounds targeting the RNA-dependent RNA polymerase Thumb-1 allosteric site.
MDL-001 demonstrated superior or equivalent efficacy to standard-of-care antivirals including sofosbuvir, oseltamivir, remdesivir, and nirmatrelvir in animal models.
Model Medicines (搜索), an AI-first biotechnology company, announced that the United States Patent and Trademark Office has granted it US Patent No. 12,551,475 B2, marking the first patent issued for its comprehensive antiviral intellectual property portfolio. The patent covers the company's lead broad-spectrum antiviral candidate MDL-001 and related compounds targeting the conserved RNA-dependent RNA polymerase (RdRp) Thumb-1 allosteric site.
Revolutionary Target Discovery Through AI
Model Medicines (搜索) overturned conventional assumptions by demonstrating the structural conservation of the RdRp Thumb-1 (搜索) allosteric pocket across viral families. The Thumb-1 site governs an essential mechanism for viral replication, interacting with the viral β1-loop to control an indispensable conformational change required for polymerase initiation. According to the company, viruses cannot abandon this mechanism without sacrificing their replicative fitness, making it an ideal therapeutic target.
The company utilized its AI-driven GALILEO platform to discover novel broad-spectrum inhibitor chemistry for this target. The research team trained GALILEO on a proprietary dataset spanning multiple viral families, enabling the model to learn the structural and chemical features underlying broad-spectrum Thumb-1 inhibition.
Comprehensive Patent Protection
The antiviral intellectual property portfolio encompasses 15 patent families covering novel compositions of matter, multi-scaffold Markush chemistry, formulations, and broad-spectrum methods of use across RNA and DNA viruses. The portfolio provides layered protection through at least 2046, structured as a multi-compound, multi-indication therapeutic franchise built around the conserved biological mechanism.
"This first patent grant signals the depth and deliberateness of the intellectual property estate we have built around our virology program generally and MDL-001 specifically," said Daniel Haders, PhD, founder and CEO of Model Medicines (搜索). "The portfolio we have constructed protects the novel Thumb-1 chemical space discovered by our GALILEO platform across scaffolds, indications, formulations and methods of use."
Broad-Spectrum Antiviral Activity
MDL-001 represents the first direct-acting antiviral shown to be potent against multiple viral families in vitro, including Orthomyxoviridae, Pneumoviridae, Coronaviridae, Flaviviridae, Komioviridae, and Hepadnaviridae. The compound has demonstrated multi-log antiviral efficacy against SARS-CoV-2 (搜索), hepatitis C virus (搜索), and hepatitis B virus (搜索) in animal models.
Notably, in vivo results demonstrate MDL-001's superiority or equivalence to multiple standards of care, including sofosbuvir, oseltamivir, remdesivir, and nirmatrelvir. This broad-spectrum activity positions MDL-001 as a potentially transformative therapeutic approach for viral infections.
Clinical Development Timeline
Model Medicines (搜索)' virology program and MDL-001 preclinical proof-of-concept data have been peer reviewed and presented at major scientific conferences including IDWeek 2025, AASLD 2025, HepDART 2025, and CROI 2026. The company will present additional data at ESCMID 2026.
The company plans to file an Investigational New Drug application with the FDA for MDL-001 in late 2026 and anticipates commencing clinical trials in 2027. This timeline reflects the advanced stage of preclinical development and the company's confidence in the therapeutic potential of its AI-discovered antiviral.
Broader Pipeline and Platform
Beyond virology, Model Medicines (搜索)' research spans infectious disease, oncology, and inflammation, with programs designed around conserved molecular choke points that drive multiple pathologies. The company has also discovered MDL-4102 (搜索), a potent, selective and novel BRD4 inhibitor, demonstrating the versatility of its GALILEO AI platform in uncovering new classes of drugs previously thought unreachable.